LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial
Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, Andrea Necchi, Mauricio Burotto, Michael Schenker, J. P. Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Y. Urun, D. Ye, Zhisong He, Begoña P. Valderrama, Y. Tomita, J. Filian, Daniela Purcea, Federico Nasroulah, Matt D. Galsky
Topics & Concepts
MedicineGemcitabineMetastatic Urothelial CarcinomaCisplatinNivolumabOncologyInternal medicinePhases of clinical researchUrologyChemotherapyUrothelial carcinomaBladder cancerCancerImmunotherapyBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersUrinary and Genital Oncology Studies